Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial
| Autor: | A Yoosefi, Shahin Akhondzadeh, Padideh Ghaeli, Mona Kargar, Asieh Ashouri, V Artonian |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Adolescent medicine.medical_treatment Young Mania Rating Scale Placebo behavioral disciplines and activities law.invention Young Adult Electroconvulsive therapy Double-Blind Method Randomized controlled trial law Internal medicine mental disorders medicine Humans Pharmacology (medical) Bipolar disorder Electroconvulsive Therapy Psychiatry Aged Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor General Medicine Middle Aged medicine.disease Combined Modality Therapy Clinical trial Psychiatry and Mental health Celecoxib Female Psychology medicine.drug |
| Zdroj: | Pharmacopsychiatry. 48:268-273 |
| ISSN: | 1439-0795 0176-3679 |
| Popis: | Introduction: The possible effect of inflammatory factors on decreasing BDNF has been proposed in the literature. There is conflicting evidence regarding association between BDNF level alteration and treatment response in depressive patients undergoing electroconvulsive therapy (ECT). This study investigated the effects of celecoxib in manic patients undergoing ECT on treatment response and BDNF levels. Methods: This randomized, double-blind, clinical trial included 35 manic patients who received either celecoxib (200 mg twice daily) or placebo, from one day before the 1st ECT session throughout the 6th session. BDNF levels were measured at baseline, 1st, 3rd and 6th ECT sessions. Young mania rating scale was used to assess treatment response. Results: Adding celecoxib was not associated with a significant rise in BDNF levels following ECT. No difference was noted between groups in terms of treatment response. No significant association was found between changes in BDNF levels and patients’ responses. Discussion: Adjuvant celecoxib did not significantly affect the BDNF level or the treatment response following ECT in manic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|